ADMA Biologics Q1 2026 Earnings EPS Miss Weighs on Shares as Profitability Path Remains in Focus DOX Q1 2026 Earnings EPS Slightly Misses Estimates Stock Edges Lower PENG Q1 2026 Earnings EPS Beats Estimates by 2065 Shares Surge IPM Q1 2026 Earnings Significant EPS Miss Despite Positive Stock Reaction Inhibikase Therapeutics IKT Q1 2026 Earnings Narrowing Losses as Pipeline Progress Takes Center Stage RILYN Q1 2024 Earnings Significant Loss Reported Revenue Not Disclosed